Krishnan, Ravi
Duiker, Melanie
Rudd, Penny A.
Skerrett, Donna
Pollard, James G. D.
Siddel, Carolyn
Rifat, Rifat
Ng, Jennifer H. K.
Georgius, Peter
Hererro, Lara J.
Griffin, Paul
Article History
Received: 2 October 2020
Accepted: 22 February 2021
First Online: 12 March 2021
Declarations
:
: The study was approved by the Bellberry Human Research Ethics Committee (HREC), Adelaide, Australia and conducted in accordance with the principles of the Declaration of Helsinki, the National Health & Medical Research Council National Statement on Ethical Conduct in Research Involving Humans, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Integrated Addendum To ICH E6(R1): Guideline For Good Clinical Practice E6(R2). It is registered at the Australian New Zealand Clinical Trials Registry #ACTRN12617000893303. All subjects provided informed consent to participate in the study.
: Not applicable.
: Donna Skerrett, Ravi Krishnan, and Melanie Duiker are employees of Paradigm Biopharmaceuticals Ltd.Lara J Hererro is the recipient of the Australian National Health and Medical Research Council Career Development Award (ID: 105760).Penny A Rudd is the recipient of an Advanced Queensland Fellowship.James GD Pollard, Carolyn Siddel, Rifat Rifat and Jennifer HK Ng have no conflicts of interest.Peter Georgius has been a paid consultant for Abbott, Boston Scientific, and Canopy Growth.Paul Griffin has no conflicts of interest.